NY-ESTÉE-LAUDER
5.4.2024 15:26:35 CEST | Business Wire | Press release
TOM FORD announced today that Dexter King has been appointed Senior Vice President, Global General Manager, TOM FORD BEAUTY. King will step into this role effective April 1, 2024 and continue reporting to Guillaume Jesel, President and CEO, TOM FORD and Luxury Business Development, The Estée Lauder Companies. King will also join The Estée Lauder Companies (NYSE:EL) Extended Executive Leadership Team.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240405576513/en/
Dexter King has been appointed Senior Vice President, Global General Manager, TOM FORD BEAUTY. (Photo: Business Wire)
King has been with TOM FORD BEAUTY for nine years, working in a number of key leadership roles including most recently as Senior Vice President (SVP), Global Marketing and Strategy, and prior to then as SVP, General Manager, International and Global Strategy. In close partnership with Jesel, under King’s leadership of strategy and International, the brand elevated key TOM FORD fragrances to the luxury tier, accelerated its channel strategy and achieved exceptional growth and share gains across key markets.
“Dexter’s multi-faceted leadership experience at TOM FORD BEAUTY has been instrumental in helping the brand achieve exceptional global growth,” said Jesel. “His deep understanding of luxury, the importance of aspirational local relevance, and his command of the strategic growth opportunities in the luxury sector make him well-suited to lead the continued global momentum of TOM FORD BEAUTY.”
In his new role, King will lead the TOM FORD BEAUTY team in all aspects of category, channel and geography strategic growth plans. He will focus on driving the brand’s luxury beauty positioning through world-class innovation across makeup, fragrance and skincare and continue to elevate the brand’s signature aspirational storytelling of modern luxury glamour and amplifying individual beauty.
Prior to TOM FORD BEAUTY, King worked in strategy and marketing roles, holding positions of increasing responsibility across companies including McKinsey & Company, Diageo, and Moët Hennessy. King holds a Master of Business Administration from The Fuqua School of Business at Duke University and a Bachelor of Arts in Economics from the University of Virginia.
About TOM FORD
TOM FORD IS A GLOBAL DESIGN HOUSE OFFERING EXCEPTIONAL LUXURY PRODUCTS ACROSS WOMEN’S AND MEN’S FASHION, ACCESSORIES, EYEWEAR AND BEAUTY. FOUNDED IN 2005 BY TOM FORD, TODAY THE BRAND HAS A PRESENCE IN MORE THAN 100 MARKETS GLOBALLY, AND IS WIDELY RECOGNIZED AS THE ARCHITECT OF LUXURY GLAMOUR. IN 2023, THE ESTÉE LAUDER COMPANIES BECAME THE SOLE OWNER OF THE TOM FORD BRAND AND ALL ITS INTELLECTUAL PROPERTY. IN APRIL 2023 PETER HAWKINGS WAS APPOINTED THE CREATIVE DIRECTOR OF TOM FORD.
About TOM FORD BEAUTY
TOM FORD IS A GLOBAL DESIGN HOUSE OFFERING EXCEPTIONAL LUXURY PRODUCTS ACROSS WOMEN’S AND MEN’S FASHION, ACCESSORIES, EYEWEAR AND BEAUTY. FOUNDED IN 2005 BY TOM FORD, TODAY THE BRAND HAS A PRESENCE IN MORE THAN 100 MARKETS GLOBALLY, AND IS WIDELY RECOGNIZED AS THE ARCHITECT OF LUXURY GLAMOUR. TOM FORD BEAUTY IS DESIGNED TO AMPLIFY INDIVIDUAL BEAUTY WITH A COLLECTION OF SUMPTUOUS COSMETICS, EXTRAORDINARY FRAGRANCES AND ADVANCED SKINCARE.
ELC-B
NYSE: EL
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240405576513/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom